<DOC>
	<DOCNO>NCT02749370</DOCNO>
	<brief_summary>evaluate efficacy etanercept adult subject moderate severe plaque fail therapy apremilast ( Otezla )</brief_summary>
	<brief_title>Study Will Evaluate Efficacy Etanercept Treatment Subjects Who Have Failed Therapy With Apremilast</brief_title>
	<detailed_description>This multicenter , open-label , single-arm , phase 4 , estimation study subject plaque psoriasis ( PsO ) fail apremilast . The study consist screen period 45 day , 24-week treatment period study visit every 4-weeks , 30-day follow-up period safety . Etanercept dose follow recommend label dose subject plaque psoriasis .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject provide informed consent prior initiation study specific activities/procedures Male female subject ≥ 18 year age time screen Subject candidate systemic therapy phototherapy opinion investigator Subject moderate severe plaque psoriasis ( PsO ) involve Body Surface Area ( BSA ) ≥ 10 % , Psoriasis Area Severity Index ( PASI ) ≥ 10 Static Physician 's Global Assessment ( sPGA ) ≥ 3 screen baseline Subject currently receive treatment apremilast moderate severe plaque PsO subject discontinue treatment apremilast PsO within past 3 month prior screen Subject fail therapy apremilast moderate severe plaque PsO define either ( 1 ) failure achieve adequate clinical response opinion investigator , ( 2 ) loss adequate clinical response opinion investigator ( 3 ) intolerability apremilast opinion investigator Subject receive least 4 week apremilast treatment moderate severe plaque PsO ( applies subject qualifying failure achieve adequate clinical response loss adequate clinical response , apply subject qualify intolerability apremilast ) Subject significant know weight increase decrease ( ≥ 10 % ) apremilast treatment Subject &lt; 264 lb screen baseline Subject negative test hepatitis B surface antigen , hepatitis B core antibody hepatitis C antibody Subject know history tuberculosis . Skin disease relate Subject active erythrodermic , pustular , guttate psoriasis , medication induce psoriasis , skin condition time screen visit ( example , eczema ) would interfere evaluation effect investigational product PsO . Other Medical Conditions Subject one significant concurrent medical condition per investigator judgment , include follow Poorly control diabetes Chronic kidney disease stage IIIb , IV , V Symptomatic heart failure ( New York Heart Association class II , III , IV ) Myocardial infarction unstable angina pectoris within past 12 month prior randomization Uncontrolled hypertension Severe chronic pulmonary disease ( eg , require oxygen therapy ) Multiple sclerosis demyelinate disease Liver disease Anemia Major chronic inflammatory disease connective tissue disease psoriasis and/or psoriatic arthritis ( example , systemic lupus erythematosus exception secondary Sjogren 's syndrome ) Subject active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma , Merkel cell carcinoma history cancer ( fully resect surgically cure cutaneous basal cell squamous cell carcinoma ) within 5 year first dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>